These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 30055340

  • 1. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ, Adams JE, Padidela R, Shaw NJ, Högler W, Roper H, Hughes I, Daniel A, Mughal MZ.
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [Abstract] [Full Text] [Related]

  • 2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J, Rybalsky I, Rutter MM.
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [Abstract] [Full Text] [Related]

  • 3. Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD).
    Crabtree NJ, Roper H, Shaw NJ.
    Bone; 2022 Jan; 154():116248. PubMed ID: 34718220
    [Abstract] [Full Text] [Related]

  • 4. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM.
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [Abstract] [Full Text] [Related]

  • 5. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R, Reddy BVC, Malviya M, Sirari T, Attri SV, Patial A, Tageja M, Didwal G, Khandelwal NK, Saini AG, Saini L, Sahu JK, Dayal D, Sankhyan N.
    J Pediatr Endocrinol Metab; 2021 May 26; 34(5):573-581. PubMed ID: 33838091
    [Abstract] [Full Text] [Related]

  • 6. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
    Mayo AL, Craven BC, McAdam LC, Biggar WD.
    Neuromuscul Disord; 2012 Dec 26; 22(12):1040-5. PubMed ID: 22824639
    [Abstract] [Full Text] [Related]

  • 7. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L, Zhou H, Xu H, Sun X, Chen X, Fan P, Cai X, Wang Q.
    Osteoporos Int; 2024 Jun 26; 35(6):997-1005. PubMed ID: 38277031
    [Abstract] [Full Text] [Related]

  • 8. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Smit K, Walker S, Hartigan C, Khan N, Konji VN, MacLeay L, Page M, Sykes E, Robinson ME, Alos N, Cummings EA, Ho J, Sbrocchi AM, Stein R, Saleh D, Craven BC, Dang UJ, Siminoski K, Rauch F, Ward LM.
    Osteoporos Int; 2023 Jan 26; 34(1):147-160. PubMed ID: 36342539
    [Abstract] [Full Text] [Related]

  • 9. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, Ahmed SF, Wong SC, UK NorthStar Clinical Network.
    JAMA Neurol; 2019 Jun 01; 76(6):701-709. PubMed ID: 30855644
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G.
    Adv Ther; 2022 Jul 01; 39(7):3308-3315. PubMed ID: 35614293
    [Abstract] [Full Text] [Related]

  • 11. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, Muntoni F, NorthStar Clinical Network.
    J Neurol Neurosurg Psychiatry; 2013 Jun 01; 84(6):698-705. PubMed ID: 23250964
    [Abstract] [Full Text] [Related]

  • 12. Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy.
    Lee SL, Lim A, Munns C, Simm PJ, Zacharin M.
    Horm Res Paediatr; 2020 Jun 01; 93(2):108-118. PubMed ID: 32610327
    [Abstract] [Full Text] [Related]

  • 13. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT, Joseph S, Capaldi N, Brown S, Di Marco M, Dunne J, Horrocks I, Shepherd S, Ahmed SF, Wong SC.
    Eur J Pediatr; 2019 May 01; 178(5):633-640. PubMed ID: 30762116
    [Abstract] [Full Text] [Related]

  • 14. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment.
    Tung JY, Lam TP, Chan SH.
    J Bone Miner Metab; 2021 Jul 01; 39(4):606-611. PubMed ID: 33400004
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.